151 related articles for article (PubMed ID: 11181644)
1. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.
Medhat A; Arzumanyan A; Feitelson MA
Oncotarget; 2021 Nov; 12(24):2421-2433. PubMed ID: 34853663
[TBL] [Abstract][Full Text] [Related]
3. Moving Fast Toward Hepatitis B Virus Elimination.
Bassit L; Ono SK; Schinazi RF
Adv Exp Med Biol; 2021; 1322():115-138. PubMed ID: 34258739
[TBL] [Abstract][Full Text] [Related]
4. Regulation Between HSF1 Isoforms and HSPs Contributes to the Variation in Thermal Tolerance Between Two Oyster Congeners.
Liu Y; Li L; Qi H; Que H; Wang W; Zhang G
Front Genet; 2020; 11():581725. PubMed ID: 33193707
[TBL] [Abstract][Full Text] [Related]
5. Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus.
Teppa E; Nadalin F; Combet C; Zea DJ; David L; Carbone A
Virus Evol; 2020 Jan; 6(1):veaa006. PubMed ID: 32158552
[TBL] [Abstract][Full Text] [Related]
6. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.
Abreu RM; Bassit LC; Tao S; Jiang Y; Ferreira AS; Hori PC; Ganova-Raeva LM; Khudyakov Y; Schinazi RF; Carrilho FJ; Ono SK
Antivir Ther; 2019; 24(8):567-579. PubMed ID: 31799942
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.
Zhang Y; Zhang H; Zhang J; Zhang J; Guo H
Antiviral Res; 2019 May; 165():47-54. PubMed ID: 30902704
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
9. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Cathcart AL; Chan HL; Bhardwaj N; Liu Y; Marcellin P; Pan CQ; Shalimar ; Buti M; Cox S; Parhy B; Zhou E; Martin R; Chang S; Lin L; Flaherty JF; Kitrinos KM; Gaggar A; Izumi N; Lim YS
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038044
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.
Lok AS; Ganova-Raeva L; Cloonan Y; Punkova L; Lin HS; Lee WM; Ghany MG;
J Viral Hepat; 2017 Nov; 24(11):1032-1042. PubMed ID: 28581155
[TBL] [Abstract][Full Text] [Related]
11. Overview of hepatitis B viral replication and genetic variability.
Tong S; Revill P
J Hepatol; 2016 Apr; 64(1 Suppl):S4-S16. PubMed ID: 27084035
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B.
Abreu RM; da Silva Ferreira C; Ferreira AS; Remor E; Nasser PD; Carrilho FJ; Ono SK
Infect Dis Ther; 2016 Mar; 5(1):53-64. PubMed ID: 26757720
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Kim J; Lee SH; Kim HS; Choi K; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
Gut Liver; 2015 Jan; 9(1):103-8. PubMed ID: 25287170
[TBL] [Abstract][Full Text] [Related]
14. Management of antiviral drug resistance in chronic hepatitis B.
Bang KB; Kim HJ
World J Gastroenterol; 2014 Sep; 20(33):11641-9. PubMed ID: 25206270
[TBL] [Abstract][Full Text] [Related]
15. Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea.
Lee AJ; Lee CH; Jeon CH
Ann Lab Med; 2014 May; 34(3):230-4. PubMed ID: 24790911
[TBL] [Abstract][Full Text] [Related]
16. Update on entecavir in the management of severe forms of Hepatitis B.
Sacco R
Hepat Med; 2012; 4():39-47. PubMed ID: 24696620
[TBL] [Abstract][Full Text] [Related]
17. An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Stalke P; Rybicka M; Wróblewska A; Dreczewski M; Stracewska E; Smiatacz T; Bielawski KP
Med Sci Monit; 2014 Feb; 20():321-8. PubMed ID: 24569300
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of entecavir for chronic hepatitis B in Chinese patients.
Wang J
Drug Des Devel Ther; 2013 Dec; 8():13-24. PubMed ID: 24376343
[TBL] [Abstract][Full Text] [Related]
19. A granulomatous drug eruption induced by entecavir.
Yoon J; Park D; Kim C
Ann Dermatol; 2013 Nov; 25(4):493-5. PubMed ID: 24371400
[TBL] [Abstract][Full Text] [Related]
20. Direct acting antivirals for the treatment of chronic viral hepatitis.
Karayiannis P
Scientifica (Cairo); 2012; 2012():478631. PubMed ID: 24278700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
